Synchron Raises $200M for Brain-Computer Interface Launch
Synchron has secured $200 million to accelerate pivotal trials and prepare for the commercial release of its Stentrode brain-computer interface (BCI) system. This funding round will support both the immediate launch and long-term development of advanced technology.
BCI Technology and Market Landscape
Brain-computer interface companies develop devices that capture and interpret brain signals to trigger actions, such as hands-free control of digital devices. However, these devices vary significantly in design and approach.
- Neuralink, led by Elon Musk, implants its device by removing a section of the skull.
- Synchron’s Stentrode is less invasive, inserted via a catheter procedure.
Each design balances invasiveness against the quality of signal data captured. For example, Synchron’s first-generation Stentrode has 16 electrodes, whereas Neuralink’s N1 Implant features 1,024 electrodes. Despite this difference, Stentrode allows severely paralyzed individuals to control personal technology effectively.
Future Developments and AI Integration
The Series D funding enables Synchron to capitalize on the benefits of its initial product while addressing its current limitations. The company is also developing a next-generation, transcatheter, high-channel whole-brain interface to improve performance.
Artificial intelligence plays a key role in Synchron’s strategy. The company is expanding its AI team in New York City to train models capable of decoding brain signals in real time.
“Synchron’s goal is to decode thought in real time.”
This real-time decoding aims to enhance the interaction between the brain and external devices, expanding capabilities for users with severe paralysis.
Summary
Synchron’s $200M funding accelerates trials and commercial readiness for its less invasive BCI, while AI-driven next-gen development aims to unlock real-time thought decoding.